LIDDS participates in partnering events

UPPSALA, SWEDEN - LIDDS AB (publ) announces today that the company will participate in BIO Europe on 24 to 26 October 2022 and Partnerships in Drug Delivery on 24 and 25 October 2022.

LIDDS' CBDO Annette Møldrup participates in BIO Europe, which is physically organized in Leipzig between 24 and 26 October 2022 in combination with a digital event between 2 and 4 November 2022. Bio Europe gathers over 4,000 participants from more than sixty countries. Opportunities for both collaboration and partner discussions as well as investor meetings are provided. In total, more than 2,200 companies participate.

LIDDS' CSO Matthew Lindon participates in PODD – Partnerships in Drug Delivery, which is organized in Boston, USA on 24 and 25 October 2022. PODD combines partnering with access to both business and scientific content in the field of drug delivery. The event has over 500 attendees representing over 20 countries.

For additional information, please contact

Anders Månsson, CEO Phone: +46 (0)70 860 47 38 E-mail: nina.herne@liddspharma.com

Jenni Björnulfson, CFO Phone: +46 (0)70 855 38 05 E-mail: jenni.bjornulfson@liddspharma.com

LIDDS' Certified Adviser is Redeye AB

LIDDS in brief:

LIDDS is a Swedish drug delivery company based on the proprietary technology NanoZolid®. With NanoZolid®, LIDDS can formulate drugs for local administration, with a maintained and controlled release for up to six months. The technology is versatile, can be used across different drug classes and solve problems within many indication areas. LIDDS offers the NanoZolid® technology to partners and has developed its own pipeline focused on oncology, where the technology enables delivery of a local and high drug dose, administered over time with very limited side effects. LIDDS has a broad pipeline with several projects in clinical development, both in early and late-stage development, and projects about to enter clinical phase. The company is listed on Nasdaq First North Growth market.

LIDDS Virdings allé 32 B SE-754 50 Uppsala www.liddspharma.com



PRESS RELEASE 18 October 2022 09:30:00 CEST

Attachments

LIDDS participates in partnering events

LIDDS Virdings allé 32 B SE-754 50 Uppsala www.liddspharma.com